56687-85-5

Usage

Uses

Used in Pharmaceutical Industry:
(Z)-7-[2β-[(1E,3R)-3-Hydroxy-4-(3-chlorophenoxy)-1-butenyl]-3α,5α-dihydroxycyclopentane-1α-yl]-5-heptenoic acid methyl ester is used as a pharmaceutical compound for its potential therapeutic properties. The molecule's unique structure and functional groups may allow it to interact with specific biological targets, making it a candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, (Z)-7-[2β-[(1E,3R)-3-Hydroxy-4-(3-chlorophenoxy)-1-butenyl]-3α,5α-dihydroxycyclopentane-1α-yl]-5-heptenoic acid methyl ester can be used as a starting material or a synthetic intermediate for the development of novel compounds with specific applications. Its unique structure may provide insights into the design and synthesis of new molecules with tailored properties.
Used in Material Science:
(Z)-7-[2β-[(1E,3R)-3-Hydroxy-4-(3-chlorophenoxy)-1-butenyl]-3α,5α-dihydroxycyclopentane-1α-yl]-5-heptenoic acid methyl ester may also find applications in material science, where its unique structure and functional groups could be exploited to create new materials with specific properties, such as improved mechanical strength, thermal stability, or chemical resistance.

InChI:InChI=1/C23H31ClO6/c1-29-23(28)10-5-3-2-4-9-19-20(22(27)14-21(19)26)12-11-17(25)15-30-18-8-6-7-16(24)13-18/h2,4,6-8,11-13,17,19-22,25-27H,3,5,9-10,14-15H2,1H3/b4-2-,12-11+/t17?,19?,20-,21?,22?/m1/s1

Upstream product

• 54276-21-0 (+)-cloprostenol 
• 74-88-4 methyl iodide 
• 52267-81-9 (3aR,4R,5R,6aS)-4-[(E)-4-(3-Chloro-phenoxy)-3-hydroxy-but-1-enyl]-5-hydroxy-hexahydro-cyclopenta[b]furan-2-one 
• 89560-44-1 (3aR,4R,5R,6aS)-4-[(E)-4-(3-Chloro-phenoxy)-3-hydroxy-but-1-enyl]-hexahydro-cyclopenta[b]furan-2,5-diol 
• 130325-32-5 Formic acid (3aR,4S,5R,6aS)-4-formyloxymethyl-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 53872-62-1 Cloprostenol 
• 62961-72-2 Corey aldehyde 
• 26054-46-6 (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one 
• 32233-40-2 (3aR,4S,5R,6aS)-5-hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 

Downstream Products

• 68399-12-2 16-(3-chlorophenoxy)-17,18,19,20-tetranor-2,3-trans-5,6-trans-tetradehydroprostaglandin F_1α methyl ester 
• 62559-75-5 (E)-7-[(1R,2R,3R,5S)-2-[(E)-(R)-4-(3-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3,5-bis-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-2-phenylselanyl-hept-5-enoic acid methyl ester 
• 69222-86-2 (2E,5E)-7-[(1R,2R,3R,5S)-2-[(E)-(R)-4-(3-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3,5-bis-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hepta-2,5-dienoic acid methyl ester 
• 69222-88-4 16-(3-chlorophenoxy)-17,18,19,20-tetranor-5,6-trans-didehydroprostaglandin F_1α methyl ester 9,11,15-tris(tetrahydropyran-2-yl ether) 
• 69222-87-3 16-(3-chlorophenoxy)-17,18,19,20-tetranor-5,6-trans-didehydroprostaglandin F_1α methyl ester 

Relevant academic research and scientific papers

Side-modified 15-deoxy-Δ12,14-prostaglandin D2, precursor of corresponding PGJ2. Synthesis from cloprostenol and anticancer activity

The title compound, a possible precursor of metabolically stable corresponding PGJ2, was obtained from cloprostenol in seven steps. The compound demonstrated cytotoxicity against the HEK 293, Hep G2 and Jurkat cell lines.

Design and synthesis of 13,14-dihydro prostaglandin F(1α) analogues as potent and selective ligands for the human FP receptor

The in vitro evaluation of a new class of potential bone anabolic agents for the treatment of osteoporosis is described. These compounds are potent and selective ligands for the human prostaglandin F receptor (hFP receptor). The compounds lack the olefin unsaturation required for potency in the natural ligand PGF(2α) yet retain binding affinity for the hFP receptor in the nanomolar to micromolar range. Removal of the alkenes also results in a better selectivity ratio for the hFP receptor over the other prostaglandin receptors tested. A rationale for the selectivity differences of various analogues, based on ligand docking experiments to a putative hFP receptor model, is also described.

A selective method for the preparation of aliphatic methyl esters in the presence of aromatic carboxylic acids

2,2-Dimethoxypropane, methanol and a catalytic amount of HCl selectively esterify aliphatic carboxylic acids, in the presence of aromatic carboxylic acids, at room temperature and in high yields.